www.fdanews.com/articles/97280-jerini-receives-emea-filing-acceptance-of-its-marketing-application-for-icatibant-in-the-treatment-of-hereditary-angioedema
Jerini Receives EMEA Filing Acceptance of its Marketing Application for Icatibant in the Treatment of Hereditary Angioedema
August 16, 2007
Jerini AG announced the acceptance of its Marketing Authorization Application (MAA) by the European Medicines Evaluation Agency (EMEA) on August 15, 2007 for Icatibant in the treatment of hereditary angioedema (HAE).
Jerini